Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015
December 14 2015 - 6:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and C. difficile infection, will be reporting
its third quarter financial results for the period ending 31
October 2015 on Thursday, 17 December 2015.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office)Erik
Ostrowski / Michelle Avery (US office) |
Tel: +44 (0)1235
443 951 +1 617 225 4455 |
|
|
Cairn Financial
Advisers LLP(Nominated Adviser)Liam Murray / Tony
Rawlinson |
Tel: +44 (0)20
77148 7900 |
|
|
N+1
Singer (Broker)Aubrey Powell / Jen Boorer |
Tel: +44 (0)20
7496 3000 |
|
|
Peckwater
PR(Financial public relations, UK)Tarquin Edwards |
Tel: +44 (0)7879 458
364tarquin.edwards@peckwaterpr.co.uk |
|
|
MacDougall
Biomedical Communications(US media contact)Chris
Erdman |
Tel: +1 781 235
3060cerdman@macbiocom.com |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024